A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
A phase 1/2 trial of Toripalimab in triple-negative breast cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
Overview
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT07281976 by Nanjing Leads Biolabs Co.,Ltd, with 220 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: LBL-024 for Injection, albumin-bound Paclitaxel injection and Toripalimab Injection.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Toripalimab, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Shares Toripalimab and the tag pipeline.